Discover all OncoDNA videos explaining how OncoDNA supports cancer patients and healthcare specialists in the therapeutic decision-making process.
Scroll down to discover
Discover our great company.
The purpose of OncoDEEP is to help the oncologist find new treatment options based on a comprehensive molecular profiling of the patient’s tumor.
At OncoDNA we have developed a five-parameter immunogram to predict if a patient will respond or not to immunotherapy.
OncoSTRAT&GO gives the most comprehensive molecular profile of the tumor by analysing biomarkers in DNA, RNA and proteins in both solid and liquid biopsies.
OncoDNA has developed OncoKDM, an online platform that allows the different cancer treatment facilities around the world to benefit from the expertise of OncoDNA by interpreting their sequencing data and other tests performed in their laboratory.
The “Muddy Angel Run” is Europe’s 5 kilometer Mud Run for women of all fitness levels who want to do good while having fun. It's a breast cancer awareness activity.
Discover the after movie of OncoDNA’s participation to ESMO 2017 in Madrid (SPAIN). The occasion to present our new and innovative solutions to oncologists. We also organized a private dinner at the Museo Lazaro Galdiano.
Discover the after movie about the participation of OncoDNA at the ESMO 2016 congress. The Sunday evening, we organized a networking dinner at the Medical Museum Copenhagen.
On May 3rd 2017, OncoDNA launched their new solution, OncoKDM. KDM means Knowlegde Driven Medicine. This SaaS application will allow any cancer treatment facility to have their data interpreted with the help of the experts at OncoDNA, using their proprietary algorithms and unique knowledge database.
On 27 April, the occasion of the official launch of its monitoring solution, OncoDNA held a symposium on the personalized treatment of cancer and patient monitoring via liquid biopsies.
OncoDEEP purpose is to orientate the oncologist towards new treatment options based on a comprehensive molecular profiling of his patient’s tumor.
Description of the video in a few words or maybe one line or two...
The Deloitte Technology Fast 50 competition is an annual selection of the 50 fastest-growing technology companies within Belgium. The initiative is designed to encourage and promote entrepreneurial, fast-growing technology companies.
Christine was diagnosed in 2017 with uterus cancer. The OncoStrat&Go molecular profiling report annotated that Christine would not react positively to Dacarbazine but only to Doxorubicin. Thus avoiding her some adverse drug reactions.
According to Prof. Dr. Marc Peeters, the answer is clear, both have to exchange data and knowledge to perform the right testing in terms of biomarkers to get the right treatment options for the patient.
In July 2008 the patient (a 54-year-old female) was diagnosed with a metastatic breast cancer ER+ / PR+ / HER2+.
In 2015 the patient (a female 50-year-old) was diagnosed with a NSCLC stage IV. Based on the results generated with OncoDEEP, the oncologist decided to treat the patient with crizotinib.
63-year-old man affected by an unknown Head&Neck primary site poorly differentiated into a squamous cell carcinoma. OncoDNA observed a high expression of PD-L1 which is associated with a good prognosis for such therapy. The patient is treated with nivolumab and shows a good response with 6 months of OS for the moment.
In October 2014 the patient (a 61-year-old male, never smoker) was diagnosed for a NSCLC stage IV. Discover his story
Le Dr Jean-Loup MOUYSSET est Oncologue et fondateur de l’Association Ressource et du Centre ressource situé à Aix en Provence. Il s'agit d'un lieu d’accueil pour les personnes touchées par le cancer. Le Dr MOUYSSET utilise nos tests OncoDEEP pour l'aider dans ses choix de traitements.
For the official launch of OncoTRACE, Dr. Christian Rolfo - MD, PhD, MBAh and professor at Antwerp University (UZA) - speaks about the benefits of OncoTRACE.
Clinomics is a liquid biopsy based cancer diagnostic company which has included OncoKDM interpretation platform to study cancer biomarkers. Discover why they have chosen to work with OncoKDM.
In the "Company of the year" competition 2015 organized by Ernst & Young, OncoDNA was designated as the most promising company of the year / Lors du concours "L'entreprise de l'année" 2015 organisé par Ernst & Young, OncoDNA fut désignée Entreprise la plus prometteuse.
La RTBF parle de l'Entreprise la plus prometteuse de l'année 2015 dans son JT du soir. Petit reportage dans les laboratoires de l'IPG et visite de nos bureaux.
OncoDNA lève un capital de 7,7 millions d'euros pour financer son ambitieux programme de croissance.
Jean-Pol Detiffe, OncoDNA's CEO, interviewed for "Ziggo Kanaal 42", a regional TV in the Netherlands
Nico Coen, OncoDNA's Sales Manager, geinterviewed voor Ziggo Kanaal 42, regionale televisie in de Nederland.